Cellosaurus MDA-MB-435S (CVCL_0622)

Cell line name MDA-MB-435S
Synonyms MDA-MB-435s; MDA-MB-435 S; MDA-MB-435-S; MDAMB435S
Accession CVCL_0622
Resource Identification Initiative To cite this cell line use: MDA-MB-435S (RRID:CVCL_0622)
Comments Problematic cell line: Contaminated. Parent cell line (MDA-MB-435) has been shown to be a M14 derivative.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: KuDOS 95 cell line panel.
Microsatellite instability: Stable (MSS) (PubMed=12661003).
Sequence variation: Heterozygous for BRAF p.Val600Glu (from parent cell line).
Sequence variation: Heterozygous for TP53 p.Gly266Glu (from parent cell line).
Omics: Array-based CGH.
Omics: miRNA expression profiling.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Amelanotic melanoma (NCIt: C3802)
Derived from metastatic site: Subcutaneous; right buttock.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0417 (MDA-MB-435)
Children:
CVCL_5T70 (MDA-MB-435s-mKate2)
Sex of cell Male
Category Cancer cell line
STR profile Source(s): ATCC; CLS; PubMed=28940260

Markers:
AmelogeninX
CSF1PO11 (ATCC; CLS)
11,12 (PubMed=28940260)
D13S31712
D16S53913
D18S5113,17
D19S43314,15
D21S1130
D2S133819,24
D3S135814
D5S81812
D7S8208,10 (ATCC; CLS)
8 (PubMed=28940260)
D8S117913
FGA21
Penta D9,11
Penta E10,12
TH016,7
TPOX8,11
vWA16,18
Web pages http://www.atcc.org/support/faqs/91699/ATCC%20HTB-129%20Derivative-1051.aspx
http://www.atcc.org/support/faqs/79d25/Morphology%20of%20ATCC%20HTB-129-495.aspx
Publications

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.-F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=15677628; DOI=10.1093/carcin/bgi032
Gorringe K.L., Chin S.-F., Pharoah P., Staines J.M., Oliveira C., Edwards P.A.W., Caldas C.
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Carcinogenesis 26:923-930(2005)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=20070913; DOI=10.1186/1471-2407-10-15
Tsuji K., Kawauchi S., Saito S., Furuya T., Ikemoto K., Nakao M., Yamamoto S., Oka M., Hirano T., Sasaki K.
Breast cancer cell lines carry cell line-specific genomic alterations that are distinct from aberrations in breast cancer tissues: comparison of the CGH profiles between cancer cell lines and primary cancer tissues.
BMC Cancer 10:15-15(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33-R33(2013)

PubMed=28940260; DOI=10.1002/ijc.31067
Korch C., Hall E.M., Dirks W.G., Ewing M., Faries M., Varella-Garcia M., Robinson S., Storts D., Turner J.A., Wang Y., Burnett E.C., Healy L., Kniss D., Neve R.M., Nims R.W., Reid Y.A., Robinson W.A., Capes-Davis A.
Authentication of M14 melanoma cell line proves misidentification of MDA-MB-435 breast cancer cell line.
Int. J. Cancer 0:0-0(2017)

Cross-references
Cell line collections ATCC; HTB-129
BCRJ; 0165
CLS; 300277/p513_MDA-MB-435S
ICLC; HTL03006
Cell line databases/resources CLDB; cl7142
CCLE; MDAMB435S_SKIN
CCRID; 3111C0001CCC000015
CCRID; 3131C0001000700036
CCRID; 3142C0001000000052
LINCS_HMS; 50030
LINCS_LDP; LCL-1307
Ontologies BTO; BTO:0003941
CLO; CLO_0007638
Gene expression databases GEO; GSM149983
GEO; GSM149991
GEO; GSM149999
GEO; GSM887298
GEO; GSM888373
GEO; GSM1374657
Polymorphism and mutation databases Cosmic; 809237
Cosmic; 871155
Cosmic; 894089
Cosmic; 904381
Cosmic; 1044202
Cosmic; 1046951
Cosmic; 1287922
Cosmic; 1289399
Cosmic; 1523969
Cosmic; 1609477
Cosmic; 2301531